Carotid
Artery Disease Treatment Market: Information by Diagnosis & Treatment
(Carotid Artery Disease and Antihypertensive Drugs), by End User (Hospital
& Clinics, Ambulatory Surgical Centers and Pharmacies) and by Region
(Americas, Europe, Asia-Pacific and the Middle East & Africa) - Forecast
till 2023
Market Overview
The
global Carotid Artery Disease Treatment Market is slated to display a CAGR of 4.1% from
2017 to 2023 (forecast period). It can touch a value of USD 11,621.6 million by
2023. The growing geriatric populace, the rising adoption of unhealthy
lifestyles by patients, and sales of over-the-counter (OTC) drugs are main
drivers of the market. Efforts by pharmaceutical manufacturers for the
production of therapeutic drugs can facilitate market growth.
The
rise of tobacco consumption is likely to warrant the demand in the market till
the end of the forecast period. According to the World Health Organization
(WHO), strokes accounted for 17 million annually. The demand for preventive
diagnosis and treatment methods for CAD can bode well for the market till 2023.
Medications prescribed for the treatment of CAD include tissue plasminogen
activator (tPA), anticoagulant medications, and antiplatelet medications.
Awareness
campaigns by governments and pharma firms for enlightening patients and raising
sufficient wherewithal are predicted to bolster the market demand. But high
cost of these medications and surgical options are challenges faced by the
market.
Carotid
arteries are blood vessels in the neck which supply oxygen to the brain.
Carotid artery disease (CAD) is a medical condition in which plaques in the
blood vessels prevent oxygen supply and cause strokes. Various medicines are
used for reducing the plaque amount or surgical techniques are employed by
doctors to help restore normal blood flow. The global Carotid Artery Disease
Treatment Market report compiled by analysts at Market Research Future (MRFR)
outlines the various drivers, challenges, and opportunities faced by the
players during the period of 2017 to 2023.
Segmentation
The
global carotid artery disease treatment market is segmented by diagnosis &
treatment and end-user.
By
diagnosis & treatment, it is segmented into diagnosis and treatment. The
treatment segment is divided into medications and surgical procedures.
Medications comprise antihypertensive drugs, antiplatelet drugs, and
cholesterol-lowering statins. On the other hand, surgical procedures encompass
carotid artery bypass, carotid artery angioplasty & stenting, and carotid
endarterectomy.
By
end-user, it is segmented into hospitals & clinics, pharmacies, ambulatory
& surgical centers, and others.
Browse
Complete Report :https://www.marketresearchfuture.com/reports/carotid-artery-disease-market-6301
Regional Analysis
Asia
Pacific (APAC), the Americas, Europe, and the Middle East & Africa (MEA)
are the regions discussed with respect to the market report.
The
Americas accounted for 37.8% share of the global Carotid Artery Disease
Treatment Market in 2017. Factors driving the regional market growth include
supportive regulations for drug development, rising prevalence of chronic
diseases, and rising levels of cholesterol in patients. According to the 2014 report
by Surgeon General, close to 400,000 patients with ages of 70 and above
suffered from asymptomatic carotid artery stenosis.
The
Europe Carotid Artery Disease Treatment Market is anticipated to expand its
share globally due to increased healthcare spending of patients, increased
healthcare budget of economies, government funding for research on chronic
diseases, and growth in the biopharmaceutical sector. Rising number of
diabetics in the region can drive the market growth. This is supported by the
rising number of diabetics purported to touch 59.8 million in 2015, as per the
report by the World Diabetes Foundation Organization.
The
APAC region is expected to expand due to considerable investments by major
players, development of new healthcare infrastructure, subsidies given to
producers, and the large number of research organizations. India possesses the
potential of generating maximum revenue to the region due to the large number
of clinical trials. In addition, the mushrooming of contract research
organizations to cater to the needs of major pharmaceutical and
biopharmaceutical firms can bode well for the market.
Competition Outlook
Silk
Road Medical, Inc., Boston Scientific Corporation, Stryker Corporation,
Medtronic, Cardinal Health, Terumo Corporation, Hitachi, Ltd, Becton, Dickinson
and Company, Abbott, W. L. Gore & Associates, Inc., and others are
noteworthy participants of the global Carotid Artery Disease Treatment Market.
Product approvals of latest products by federal agencies can bode well for
these players.
Industry News
Carotid
artery imaging is a brand new diagnostic procedure as per the new findings in
the Journal of Computer-assisted Tomography. The study concluded its efficacy
in determining the presence of cardiovascular diseases and preventing the
probability of strokes.
No comments:
Post a Comment